Newsroom Stories

A study from School of Medicine researchers, published in the journal Nature, has found evidence that the immune response to the first two COVID-19 vaccines authorized by the FDA is both strong and potentially long-lasting.

The virus that causes COVID-19 normally gets inside cells by attaching to a protein called ACE2. School of Medicine researchers have found that a single mutation confers the ability to enter cells through another route.

Mimi Calter, deputy university librarian at Stanford University, has been appointed vice provost and university librarian at Washington University, according to Provost Beverly Wendland. Calter will join the university in the fall.

“We often think about genres of love narratives, whether they’re films or novels, as frivolous,” said Jessica Rosenfeld, of Arts & Sciences. “But in the Middle Ages, love stories, love narratives, love songs, were invested with the highest seriousness.”

Researchers at the School of Medicine have identified ingredients for snack food prototypes that have been formulated to deliberately change the gut microbiome in ways that can be linked to health.

Using a diverse set of tools, the lab of Randall Martin shows how the pandemic did – or didn’t – affect levels of particulate matter during COVID lockdowns.

Washington University in St. Louis is welcoming the first round of faculty members identified through its race and ethnicity cluster hire initiative, a multiyear effort to build a world-class and interdisciplinary research program on race.

An investigational Alzheimer’s drug showed mixed results, reducing molecular markers of disease and curbing neurodegeneration, without demonstrating evidence of cognitive benefit, in a clinical trial led by School of Medicine researchers.

Researchers at Washington University School of Medicine have found that high levels of a normal protein associated with reduced heart disease also protect against Alzheimer’s-like damage in mice, opening up new approaches to slowing or stopping brain damage and cognitive decline in people with Alzheimer’s.

New research at Washington University School of Medicine suggests that many COVID-19 therapies made from combinations of two antibodies are effective against a wide range of variants of the virus.